Rice Hall James & Associates LLC increased its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 273.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 271,897 shares of the company's stock after purchasing an additional 199,110 shares during the period. Rice Hall James & Associates LLC owned 1.16% of UroGen Pharma worth $3,453,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Coastal Bridge Advisors LLC boosted its position in UroGen Pharma by 4.1% during the 2nd quarter. Coastal Bridge Advisors LLC now owns 38,500 shares of the company's stock valued at $646,000 after acquiring an additional 1,500 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in UroGen Pharma by 90.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company's stock valued at $103,000 after purchasing an additional 3,856 shares in the last quarter. ARK Investment Management LLC grew its stake in UroGen Pharma by 3.7% in the second quarter. ARK Investment Management LLC now owns 151,781 shares of the company's stock valued at $2,547,000 after purchasing an additional 5,452 shares during the last quarter. ProShare Advisors LLC bought a new position in UroGen Pharma in the second quarter worth about $199,000. Finally, Rhumbline Advisers lifted its position in shares of UroGen Pharma by 37.2% during the second quarter. Rhumbline Advisers now owns 50,477 shares of the company's stock valued at $847,000 after buying an additional 13,681 shares during the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages have recently issued reports on URGN. Oppenheimer reaffirmed an "outperform" rating and issued a $40.00 price objective on shares of UroGen Pharma in a research report on Wednesday, October 16th. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 price target on shares of UroGen Pharma in a report on Tuesday, October 15th. Guggenheim initiated coverage on UroGen Pharma in a report on Thursday, August 22nd. They set a "buy" rating and a $40.00 price objective for the company. Finally, EF Hutton Acquisition Co. I raised UroGen Pharma to a "strong-buy" rating in a research report on Monday, October 14th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $48.38.
Get Our Latest Research Report on URGN
NASDAQ URGN opened at $12.20 on Friday. UroGen Pharma Ltd. has a 12-month low of $10.60 and a 12-month high of $20.70. The company has a fifty day simple moving average of $12.95 and a two-hundred day simple moving average of $14.24. The company has a quick ratio of 7.93, a current ratio of 8.15 and a debt-to-equity ratio of 3.23.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.09). The company had revenue of $21.85 million during the quarter, compared to the consensus estimate of $23.69 million. On average, equities research analysts expect that UroGen Pharma Ltd. will post -3.49 earnings per share for the current year.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.